Advanced Cancer Clinical Trial
Official title:
A Study to Determine Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Therapy of Metastases to Bone
The goal of this clinical research study is to learn how well magnetic resonance thermal imaging (MRTI) can check the amount of tumor being destroyed using a therapy called laser ablation (a procedure that uses lasers to create heat that is designed to destroy cancer cells).
Laser ablation is designed to destroy tumor tissue with the use of fiber optics that are
placed directly into the tumor to deliver laser light energy into the tissue.
In this study, tumor destruction will be checked using MRTI. MRTI is very similar to other
MRI techniques, but instead of providing imaging data, MRTI will provide temperature data for
cancerous areas in the body during the laser ablation process. If tumor temperature can be
measured more accurately, the laser ablation process may be safer.
Laser Ablation and the MRTI Scan:
If you are found to be eligible to take part in this study, on the day you have laser
ablation, you will have an intravenous (IV) line placed. You will receive sedation or general
anaesthesia (drugs to make you sleep) through a needle in your vein over 1-3 hours to lessen
any pain you may have during the procedure. This process will be explained to you.
After receiving the anaesthesia, the following tests and procedures will be performed:
- You will have a limited MRI.
- Your skin will be cleaned and covered with sterile towels and sheets to lower the chance
of an infection.
- The doctor will use MRI scans to place a special needle (applicator) into the tumor.
This applicator will be used to create heat at a high enough temperature that cells can
be destroyed. Small masses may be destroyed in 1 treatment, but larger masses may
require that the needle is placed several times. Each heating cycle takes less than 10
minutes.
- During laser ablation, MRTI will be used to monitor the temperature within the ablation
zone. The MRTI process is very similar to regular MRI.
- Your heart rate and blood pressure will be measured during the entire procedure.
- The entire procedure may take about 1-3 hours, depending on the size and location of
your tumor.
After the procedure is completed, you will be kept in the hospital for 4-6 hours for
observation. You will be checked for recovery from the sedation that you received during the
procedure. Once you have recovered from the procedure, you will be allowed to leave the
hospital. If you have side effects from the procedure, the doctor may decide to keep you in
the hospital for a longer time period for observation.
Follow-Up Visits:
After you have completed the procedure, you will return to M. D. Anderson for follow-up
visits. About one (1) week after the laser ablation, you will have a physical exam and an
X-ray. About one (1) month after the laser ablation, you will have a physical exam and a
limited MRI to check the status of the disease.
Length of Study:
You will be considered off-study after the 1-month follow up visit.
This is an investigational study. The laser ablation procedure is an FDA-approved procedure.
The devices are commercially available and can be used outside research studies. The
investigational part of this study involves using MRTI to check the effect of ablation on the
tumor. Up to 24 participants will be enrolled in this study. All will be enrolled at M.D.
Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |